Ascletis Pharma Inc. has shared preliminary results from its U.S. Phase Ib study testing ASC30, a long-lasting small molecule GLP-1 receptor agonist. The subcutaneous version of ASC30 showed an observed half-life of 36 days in people with obesity (BMI between 30 and 40 kg/m²), which suggests it could be taken once a month or even less often. This extended duration is made possible by Ascletis’ proprietary Ultra-Long-Acting Platform (ULAP). In this single-dose study, participants who received 100 mg of ASC30 reached their highest drug levels at 17 days after injection, with a peak-to-trough ratio of less than 2:1, indicating a slow and steady drug release pattern that may support long-term tolerability.
Health Technology Insights: Tolion to Launch AI Brain Coach App Beta on Sept 17, 2025
Jinzi Jason Wu, Ph.D., Founder, Chairman, and CEO of Ascletis, said the findings highlight the potential of ASC30 as a once-monthly injectable alternative to existing weekly treatments. He explained that reducing the number of injections and medical devices required can make treatment more convenient for patients and improve long-term adherence. He also emphasized that ASC30’s flexibility—available both as a daily oral treatment and a monthly injectable—offers meaningful choices for people managing obesity or associated health issues.
Health Technology Insights: Meroka Launches with $6 Million Seed Round to Restore Humanity in Healthcare
The subcutaneous formulation of ASC30 is among the most advanced small molecule GLP-1 receptor agonists under development for monthly use. The safety results from the trial were also positive. There were no serious side effects or high-grade adverse events reported. A small number of participants experienced mild gastrointestinal symptoms, and no abnormalities were observed in liver function tests. These results support the potential for ASC30 to be used as a well-tolerated long-acting treatment that maintains consistent drug levels and avoids the side effects often triggered by higher peak doses.
In parallel with the Phase Ib study, Ascletis is conducting a Phase IIa trial in the United States to evaluate ASC30’s effectiveness when used monthly in individuals with obesity or those who are overweight and have at least one related health condition. The 12-week study is focused on assessing safety, tolerability, and early signs of clinical benefit. Ascletis expects to report topline data from this study in the first quarter of 2026.
With ASC30, Ascletis aims to reshape obesity treatment by offering a long-acting, flexible, and patient-friendly therapeutic option. Its extended duration, positive safety profile, and simplified dosing schedule may significantly improve the overall experience for patients, leading to better treatment outcomes and greater long-term success in weight management.
Health Technology Insights: Atelerix and Rodon Global Partner on Cryo-Free Biotech Shipping
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
